Previous 10 | Next 10 |
2023-07-11 08:20:47 ET Viridian Therapeutics VRDN -19% following thyroid eye disease asset data . ADC Therapeutics ( ADCT ) -16% announces voluntary pause of enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in unfit or frail previously untre...
2023-07-11 08:14:36 ET ADC Therapeutics ( NYSE: ADCT ) lost ~16% pre-market Tuesday after announcing a voluntary pause in enrollments in a Phase 2 trial for a drug regimen containing its lymphoma therapy Zynlonta due to treatment-emergent adverse events (TEAEs). The study, L...
LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial (ClinicalTrials.gov Identifier: NCT05144009) evaluating ZYNLONTA ® (loncastuximab tesirine-l...
Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE, Switzerland, June 15, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced th...
LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA ® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL...
LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 8 th at 8:30 a.m. EDT. A li...
2023-05-29 06:15:24 ET Summary Shares of antibody drug conjugate concern ADC Therapeutics SA are down 95% from their all-time high set in mid-2020 as tepid upside to Zynlonta sales and Cami program uncertainty. The company does have two licensing deals inked for Zynlonta and is se...
Poster presentation will highlight durable, long-term responses in relapsed/refractory DLBCL patients treated with ZYNLONTA ® ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-...
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 16 th at 10:00 a.m. EDT. A live webcast of the presentation will be ava...
2023-05-09 12:21:06 ET ADC Therapeutics SA (ADCT) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Amanda Loshbaugh - Investor Relations Manager Ameet Mallik - Chief Executive Officer Kristen Harrington-Smith - Chief Commercial Office...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...